摘要
蛋白酶主要是单核细胞和淋巴细胞中表达,负责细胞免疫的抗原肽的生成。在曝光于细胞炎症因子IFN-γ和TNF-ααγ下时,构成亚基可以被免疫核心颗粒β1i, β2i和 β5i取代。最近的研究表明,免疫蛋白酶体功能不仅限于MHC I类分子的表达,它还与许多病理疾病如血液系统恶性肿瘤、炎症和自身免疫性疾病有关。目前市售的蛋白酶体抑制剂Bortezomib 和Carfilzomib,已在多发性骨髓瘤和其他疾病中证明有效,它以免疫本构模型和免疫蛋白酶体紊乱为靶点。特异性的缺乏解释了这些药物的副作用,相反,通过选择性地靶向免疫蛋白酶体,它可能会使抗血管生成和抗淋巴瘤疗效不变,同时提高药物的治疗指数。本文旨在讨论最近几年发展起来的最有前景的免疫蛋白酶体核心颗粒的选择性抑制剂, 并主要关注于其结构特点、作用机制及治疗应用。
关键词: 免疫蛋白酶体,核心颗粒,免疫蛋白酶体的选择性抑制剂,血液系统恶性肿瘤、自身免疫性疾病、炎症性疾病。
Current Medicinal Chemistry
Title:Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, Autoimmune and Inflammatory Diseases
Volume: 23 Issue: 12
Author(s): Roberta Ettari, Santo Previti, Alessandra Bitto, Silvana Grasso, Maria Zappalà
Affiliation:
关键词: 免疫蛋白酶体,核心颗粒,免疫蛋白酶体的选择性抑制剂,血液系统恶性肿瘤、自身免疫性疾病、炎症性疾病。
摘要: The immunoproteasome is predominantly expressed in monocytes and lymphocytes and is responsible for the generation of antigenic peptides for cell-mediated immunity. Upon the exposure of inflammatory cytokines IFN-γ and TNF-α, constitutive subunits can be replaced by the synthesis of the immuno-core particles β1i, β2i and β5i. Recent studies demonstrated that the immunoproteasome function is not only limited to MHC class I presentation, but it is also implicated in a number of pathological disorders including hematological malignancies, inflammatory and autoimmune diseases. At present the commercially available proteasome inhibitors Bortezomib and Carfilzomib, which have been validated in multiple myeloma and other diseases, appear to target both the constitutive and immunoproteasomes indiscriminately. This lack of specificity may, in part, explain some of the side effects of these agents. In contrast, by selectively targeting the immunoproteasome, it may be possible to keep the antimyeloma and antilymphoma efficacy unchanged and, at the same time, to increase the therapeutic index. The aim of this review article is to discuss the most promising immunoproteasome core particle-selective inhibitors which have been developed in the recent years, with a particular attention to their structural features, mechanism of action and therapeutic application.
Export Options
About this article
Cite this article as:
Roberta Ettari, Santo Previti, Alessandra Bitto, Silvana Grasso, Maria Zappalà , Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, Autoimmune and Inflammatory Diseases, Current Medicinal Chemistry 2016; 23 (12) . https://dx.doi.org/10.2174/0929867323666160318173706
DOI https://dx.doi.org/10.2174/0929867323666160318173706 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Membrane Tyrosine Kinase Receptors are an Important Target for the Therapy of Acute Myeloid Leukemia
Current Cancer Therapy Reviews The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery HLA Peptide-mediated Strategies for Modulation of Cellular and Humoral Immune Response in Transplantation
Current Pharmacogenomics Haematopoietic Stem Cell Gene Therapy to Treat Autoimmune Disease
Current Stem Cell Research & Therapy MicroRNAs-based Therapy: A Novel and Promising Strategy for Cancer Treatment
MicroRNA Gene Expression-Based Pharmacodynamic Biomarkers: The Beginning of a New Era in Biomarker-Driven Anti-Tumor Drug Development
Current Molecular Medicine Efalizumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Fluorescent Cisplatin Analogues and Cytotoxic Activity
Current Medicinal Chemistry Human Endometrial and Ovarian Cancer Cells: Histone Deacetylase Inhibitors Exhibit Antiproliferative Activity, Potently Induce Cell Cycle Arrest, and Stimulate Apoptosis
Current Medicinal Chemistry The Expanding Role of APRIL in Cancer and Immunity
Current Molecular Medicine EBV-Related Malignancies, Outcomes and Novel Prevention Strategies
Infectious Disorders - Drug Targets S1P Regulation of Macrophage Functions in the Context of Cancer
Anti-Cancer Agents in Medicinal Chemistry Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Current Trends in the Chemotherapy of Colorectal Cancer
Current Medicinal Chemistry Schizophrenia: A Systematic Review of the Disease State, Current Therapeutics and their Molecular Mechanisms of Action
Current Medicinal Chemistry Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design Novel and Emerging Drugs for Rarer Chronic Lymphoid Leukaemias
Current Cancer Drug Targets Drug-Mediated Targeted Disruption of Multiple Protein Activities Through Functional Inhibition of the Hsp90 Chaperone Complex
Current Medicinal Chemistry Role of Pemetrexed and Platinums Combination in Patients with Non- Small Cell Lung Cancer
Current Drug Targets